In a review published in the journal Science, researchers from the University of Gothenburg and the University of Copenhagen examined how medications used to treat obesity and type 2 diabetes might also protect brain function. Agents such as semaglutide and tirzepatide are widely prescribed for weight management and metabolic regulation, but they also influence biological processes essential to cognitive health. The authors assessed the current body of evidence to outline how a deeper understanding of these mechanisms could guide new therapeutic approaches to safeguard memory and other vital cognitive faculties.
According to the review, preclinical investigations in animals demonstrate that GLP-1 drugs can influence learning and memory processes, yet findings in humans remain mixed. Observational analyses of patient records have linked GLP-1 treatment to a decreased risk of dementia among individuals with type 2 diabetes. However, the researchers emphasize that these retrospective health records cannot determine causality or confirm whether the medications themselves are directly responsible for the reduced risk.
In Novo Nordisk’s EVOKE and EVOKE+ clinical trials, semaglutide failed to slow clinical disease progression in patients diagnosed with early Alzheimer’s disease. Notably, the lack of clinical slowing occurred despite observed alterations across several biological markers associated with the disease.
The authors note that these clinical trial outcomes in Alzheimer’s disease do not rule out potential cognitive benefits in alternative patient groups. Individuals with obesity or type 2 diabetes often encounter measurable difficulties with attention, planning, and information processing speed. Because these problems are often linked to metabolic and vascular health, they may therefore respond better to treatment.
A critical question highlighted by the research team is whether the cognitive effects of these medications arise from indirect systemic metabolic improvements, direct actions within the brain, or an interplay of both. First author Stina Börchers emphasized the necessity of investigating whether such pharmacotherapies can preserve cognitive abilities if administered before impairments become firmly established, while also identifying the patient populations most likely to experience meaningful benefit.
Senior author Christoffer Clemmensen noted that increasingly sophisticated obesity therapies offer new avenues to study how metabolic control impacts neurological function, potentially enabling the design of treatments targeted at preserving cognition. To resolve current uncertainties, the authors call for future clinical trials designed to systematically track memory and other cognitive outcomes from the start of treatment. Furthermore, they stress the importance of carefully monitoring frail and older patients, for whom rapid weight loss and accompanying muscle loss could compromise physical functioning and diminish overall therapeutic benefits.
Subject of Research: Effects of obesity and diabetes pharmacotherapies on brain function and cognition
Article Title: Obesity drugs could lead to new ways to protect the brain
Article References: Obesity drugs could lead to new ways to protect the brain. Original publication (Bibliographic details unavailable.)
Image Credits: AI Generated
DOI: Not provided
Keywords: obesity drugs, semaglutide, tirzepatide, GLP-1, type 2 diabetes, cognition, memory, learning, dementia, Alzheimer's disease, EVOKE trial, EVOKE+ trial, metabolic health, vascular health, processing speed, muscle mass loss, Stina Börchers, Christoffer Clemmensen
News Source: Cassandra Pierce. (November 14, 2026). Review Assesses How Obesity Drugs Might Help Protect Brain Function. Scienmag.



